Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, 2025 (GLOBE NEWSWIRE) — Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products […]
Read more